CEL-SCI receives intent to grant notice for new Multikine patent from the EPO
CEL-SCI announced it has been notified that it will be granted a new patent on Multikine (Leukocyte Interleukin, Injection), its investigational cancer immunotherapy, from the European Patent Office. The patent relates to a method for altering the composition of tumor infiltrating mononuclear cells. April 28, 2017